| Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. | |
| | |
MedLine Citation:
|
PMID: 10178498 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this cohort pilot study was to compare the resource utilization and economic outcomes associated with the use of risperidone versus haloperidol in a naturalistic setting. Patient charts from a large psychiatric group practice were reviewed, and hospital billing data were obtained. Patients meeting the inclusion criteria were placed into one of two cohorts depending on their medication history. Thirty patients treated with risperidone met the selection criteria, and a random quota sampling technique was used to allow for a matched control cohort of 30 patients treated with haloperidol. In the haloperidol and risperidone cohorts, 24 and 28 patients, respectively, were evaluated statistically. Mean utilization rates and costs per patient per month for each service were estimated by using regression analysis. Patients in the risperidone cohort had significantly fewer hospitalizations than did those in the haloperidol cohort (P = 0.004). Likewise, risperidone patients had significantly lower hospitalization costs than haloperidol patients (P = 0.005). Conversely, patients treated with risperidone visited the physician more frequently than did those treated with haloperidol (P = 0.0005). Estimated mean total monthly costs were $123.34 lower (95% confidence interval = $464, $217) per patient in the risperidone cohort than in the haloperidol cohort ($1,636.11 vs $1759.45; P = 0.4693). Significant reductions in hospital costs in the risperidone cohort offset higher medication and physician costs. Overall, total monthly costs were similar for the two cohorts. |
| | |
Authors:
|
B S Nightengale; L Garrett; S Waugh; B J Lawrence; J Andrus |
Related Documents
:
|
11060938 - Intrusive thoughts and auditory hallucinations: a comparative study of intrusions in ps... 15992518 - Lack of evidence for elevated obstetric complications in childhood onset schizophrenia. 16507968 - Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. 22024218 - Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhib... 20737498 - Clinicopathological aspects of mucosa-associated lymphoid tissue (malt) lymphoma of the... 17213018 - A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of managed care Volume: 4 ISSN: 1088-0224 ISO Abbreviation: Am J Manag Care Publication Date: 1998 Mar |
Date Detail:
|
Created Date: 1998-05-26 Completed Date: 1998-05-26 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9613960 Medline TA: Am J Manag Care Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 360-6 Citation Subset: H |
Affiliation:
|
Applied Health Outcomes, Inc, Palm Harbor, FL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antipsychotic Agents
/
economics*,
therapeutic use Cohort Studies Group Practice / economics* Humans Mental Disorders / drug therapy Outcome Assessment (Health Care) / economics* Pilot Projects Risperidone / economics*, therapeutic use United States Utilization Review |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 106266-06-2/Risperidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A cost-effectiveness clinical decision analysis model for schizophrenia.
Next Document: Treatment of schizophrenia: let's talk dollars and sense.